June 13, 2025

Before initiating human clinical trials, sponsors must submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration.

During review, the FDA may impose a clinical hold if there are concerns about patient safety or insufficient supporting data.

While clinical holds are designed to protect participants, they can lead to:

  • Development delays 
  • Increased costs 
  • Operational disruptions 

A significant proportion of holds stem from nonclinical deficiencies, making early planning and data quality critical.

What causes an IND clinical hold?
IND clinical holds are typically caused by insufficient or inadequate nonclinical data, including missing toxicology studies, poor dose justification, or safety concerns identified in animal studies.

What Is a Clinical Hold?

A clinical hold is an official FDA action that delays or suspends a clinical investigation.

Types of Clinical Holds

TypeDescription
Complete HoldAll clinical trial activities are stopped
Partial HoldSpecific parts of the study are paused (e.g., dose group, protocol)

Common Nonclinical Triggers for Clinical Holds

Nonclinical (preclinical) data plays a critical role in demonstrating safety before human exposure.

TriggerDescriptionImpact
Missing Toxicology StudiesLack of GLP repeat-dose, genotoxicity, or safety pharmacology dataImmediately hold risk
Animal Study ConcernsSevere toxicity or carcinogenic signalsSafety concerns
Weak Dose JustificationPoor translation from animal to human doseRisk of unsafe exposure
Poor Study DesignNon-GLP studies or missing endpointsData rejection
Product Safety GapsImpurities or stability not assessedRegulatory deficiency

1. Missing or Inadequate Toxicology Studies

  • Absence of key studies such as: 
    • Repeat-dose toxicity 
    • Genotoxicity 
    • Safety pharmacology 

Studies must follow GLP standards to ensure reliability.

2. Animal Study Safety Concerns

  • Findings such as: 
    • Severe organ toxicity 
    • Carcinogenic signals 
    • Unexpected adverse effects 

Require clear mitigation strategies or justification.

3. Weak First-in-Human Dose Justification

  • Poor rationale for: 
    • Starting dose 
    • Dose escalation strategy 

Must be supported by NOAEL, MTD, or pharmacokinetic modeling.

4. Poor Study Design or Data Quality

  • Non-compliance with GLP 
  • Missing safety endpoints 
  • Incomplete datasets 

Leads to regulatory rejection or additional data requests.

5. Product-Related Safety Gaps

  • Impurities not qualified 
  • Lack of stability data 
  • Inadequate characterization 

How to Prevent an IND Clinical Hold

Proactive planning and adherence to regulatory expectations can significantly reduce risk.

Prevention Strategies

StrategyBenefit
Early nonclinical planningIdentify data gaps early
GLP-compliant studiesEnsures data acceptance
ICH guideline alignmentRegulatory consistency
Strong dose justificationReduces safety concerns
Clear documentationFaster FDA review

Key Prevention Approaches

  • Develop a targeted nonclinical strategy aligned with product type 
  • Follow international guidelines such as: 
    • ICH M3(R2) 
    • ICH S6 
    • ICH S9 
    • ICH S11 
  • Use relevant animal models 
  • Support studies with: 
    • In vitro assays 
    • In silico modeling 
  • Ensure high-quality regulatory writing and documentation

How to Respond to a Clinical Hold

If a hold is issued, a structured and timely response is critical.

Clinical Hold Resolution Workflow

StepActionObjective
ReviewAnalyze FDA hold letterUnderstand deficiencies
Gap AnalysisCompare with requirementsIdentify missing data
Data GenerationConduct targeted GLP studiesAddress gaps
Re-evaluationReassess existing dataStrengthen justification
FDA InteractionRequest Type A meetingAlign expectations
SubmissionProvide structured responseLift hold

Key Response Actions

  1. Carefully review FDA feedback 
  2. Conduct a comprehensive gap analysis 
  3. Performed targeted additional studies 
  4. Clarify and strengthen existing data 
  5. Engage with FDA through formal meetings (e.g., Type A) 
  6. Submit a clear, well-structured response package 

Common Challenges

ChallengeImpact
Misinterpretation of FDA feedbackDelayed resolution
Insufficient additional dataContinued hold
Poor documentationRejection of response
Lack of FDA engagementMisaligned expectations

Quick Facts

  • Clinical holds delay or stop IND trials 
  • Most holds are due to non-clinical gaps 
  • GLP toxicology studies are critical 
  • Strong justification is essential 
  • Early planning reduces risk 

Why IND Readiness Matters

Successful IND submissions require deep scientific expertise, regulatory experience, and strong data integrity. Authorities like the U.S. Food and Drug Administration expect robust, well-justified nonclinical evidence. Companies that invest in high-quality studies and clear documentation demonstrate credibility, reliability, and commitment to patient safety.

How Maven Scientific Laboratories Supports IND Success

Our Services

  • Nonclinical strategy development 
  • GLP toxicology study support 
  • Gap analysis and remediation 
  • Regulatory writing and IND submission support 
  • Clinical hold response strategy 

Why Choose Maven

  • Strong FDA regulatory expertise 
  • End-to-end IND support 
  • Proven experience in nonclinical compliance 
  • High-quality, audit-ready documentation 

Avoid Delays in Your IND Program

Facing IND challenges or clinical hold risks?

Partner with Maven Scientific Laboratories for robust, compliant, and FDA-ready nonclinical strategies

  1. Reducing clinical hold risk
  2. Strengthen IND submissions
  3. Accelerate development timelines

Conclusion

IND clinical holds are a critical checkpoint to ensure patient safety but they can significantly impact development timelines.

By focusing on robust nonclinical data, regulatory alignment, and proactive planning, companies can minimize risks and improve submission success.

If a hold occurs, a structured, data-driven response and proactive FDA engagement are key to resuming clinical development quickly and efficiently.

FAQs

1. What is an IND clinical hold?
A delay or suspension of a clinical trial by the FDA due to safety concerns.

2. What are common causes?
Missing toxicology data and weak dose justification.

3. How can holds be prevented?
Through strong nonclinical planning and GLP-compliant studies.

4. What is a Type A meeting?
A rapid FDA meeting to address critical issues like clinical holds.

5. How long does it take to resolve a hold?
Depends on the complexity of data gaps and response quality.

6. How can Maven help?
By supporting nonclinical strategies and clinical hold resolution.